Progenics Pharmaceuticals (PGNX) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	6 Months Ended	9 Months Ended
	Jun. 30, 2014	Sep. 30, 2014	Nov. 03, 2014
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'PROGENICS PHARMACEUTICALS INC	'	'
Entity Central Index Key	'0000835887	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	$165,112,553	'	'
Entity Common Stock, Shares Outstanding	'	'	69,555,634
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q3	'	'
Document Type	'10-Q	'	'
Amendment Flag	'false	'	'
Document Period End Date	'	30-Sep-14	'

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$85,230	$65,860
Accounts receivable, net	41,667	2,879
Auction rate securities - current	2,208	0
Other current assets	1,994	1,943
Total current assets	131,099	70,682
Auction rate securities - long-term	0	2,208
Fixed assets, at cost, net of accumulated depreciation and amortization	2,321	2,413
Intangible assets, net (Note 5)	30,800	31,379
Goodwill	7,702	7,702
Other assets	157	157
Total assets	172,079	114,541
Current liabilities:	'	'
Accounts payable and accrued expenses	6,039	6,512
Other current liabilities	115	115
Total current liabilities	6,154	6,627
Contingent consideration liability	17,100	15,700
Deferred tax liability - long term	12,093	12,321
Other liabilities	912	914
Total liabilities	36,259	35,562
Commitments and contingencies (Note 10)	'	'
Stockholders' equity:	'	'
Preferred stock, $.001 par value; 20,000,000 shares authorized; issued and outstanding - none	0	0
Common stock, $.0013 par value; 160,000,000 shares authorized; issued - 69,755,634 in 2014 and 61,025,404 in 2013	91	79
Additional paid-in capital	588,750	548,510
Accumulated deficit	-450,088	-466,677
Accumulated other comprehensive loss	-192	-192
Treasury stock, at cost (200,000 shares in 2014 and 2013)	-2,741	-2,741
Total stockholders' equity	135,820	78,979
Total liabilities and stockholders' equity	$172,079	$114,541

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Stockholders' equity:	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized	160,000,000	160,000,000
Common stock, issued	69,755,634	61,025,404
Common stock, shares outstanding (in shares)	69,555,634	60,825,404
Treasury stock, shares	200,000	200,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Collaboration revenue	$40,023	$145	$41,144	$1,512
Royalty income	1,626	719	3,728	3,052
Research grants	0	0	0	275
Other revenues	7	3	76	55
Total revenues	41,656	867	44,948	4,894
Expenses:	'	'	'	'
Research and development	6,728	7,905	21,495	26,205
License fees - research and development	10	91	280	314
Royalty expense	319	73	548	308
General and administrative	3,895	3,131	11,156	11,350
Depreciation and amortization	142	179	419	774
Intangible impairment charge	576	0	576	0
Change in contingent consideration liability	500	0	1,400	0
Total expenses	12,170	11,379	35,874	38,951
Other Operating Income	7,250	0	7,250	0
Operating income (loss)	36,736	-10,512	16,324	-34,057
Other income:	'	'	'	'
Interest income	12	12	37	36
Total other income	12	12	37	36
Net income (loss) before income tax benefit	36,748	-10,500	16,361	-34,021
Income tax benefit	227	0	228	0
Net income (loss)	$36,975	($10,500)	$16,589	($34,021)
Net income (loss) per share - basic	$0.53	($0.17)	$0.24	($0.63)
Weighted-average shares - basic	69,556	60,599	67,712	54,104
Net income (loss) per share - diluted	$0.51	($0.17)	$0.24	($0.63)
Weighted-average shares - diluted	72,879	60,599	67,727	54,104

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) [Abstract]	'	'	'	'
Net income (loss)	$36,975	($10,500)	$16,589	($34,021)
Other comprehensive income:	'	'	'	'
Net change in unrealized loss on auction rate securities	0	0	0	68
Total other comprehensive income	0	0	0	68
Comprehensive income (loss)	$36,975	($10,500)	$16,589	($33,953)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total
In Thousands, except Share data
Balance, beginning at Dec. 31, 2012	$61	$493,613	($424,105)	($260)	($2,741)	$66,568
Balance, beginning (in shares) at Dec. 31, 2012	46,765,000	'	'	'	-200,000	'
Net income (loss)	'	'	-34,021	'	'	-34,021
Other comprehensive income	'	'	'	68	'	68
Compensation expenses for share-based payment arrangements	'	2,903	'	'	'	2,903
Acquisition of subsidiary, net of issuance costs	6	11,214	'	'	'	11,220
Stock Issued During Period, Shares, Acquisitions	4,472,000	'	'	'	'	'
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses	12	40,067	'	'	'	40,079
Public Offering shares issued	9,775,000	'	'	'	'	'
Acquisition of subsidiary escrow shares returned	'	'	'	'	'	0
Forfeitures of restricted stock (in shares)	-1,000	'	'	'	'	'
Exercise of stock options	'	71	'	'	'	71
Exercise of stock options (in shares)	14,000	'	'	'	'	'
Balance, ending at Sep. 30, 2013	'	547,868	-458,126	-192	-2,741	86,888
Balance, ending (in shares) at Sep. 30, 2013	61,025,000	'	'	'	-200,000	'
Balance, beginning at Dec. 31, 2013	79	548,510	-466,677	-192	-2,741	78,979
Balance, beginning (in shares) at Dec. 31, 2013	61,025,000	'	'	'	-200,000	'
Net income (loss)	'	'	16,589	'	'	16,589
Compensation expenses for share-based payment arrangements	'	2,875	'	'	'	2,875
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses	12	37,447	'	'	'	37,459
Public Offering shares issued	8,750,000	'	'	'	'	8,750,000
Acquisition of subsidiary escrow shares returned - shares	-19,000	'	'	'	'	'
Acquisition of subsidiary escrow shares returned	'	-82	'	'	'	-82
Balance, ending at Sep. 30, 2014	$91	$588,750	($450,088)	($192)	($2,741)	$135,820
Balance, ending (in shares) at Sep. 30, 2014	69,756,000	'	'	'	-200,000	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Underwriting discounts and commissions	$2,415	$2,581
Offering expenses	$376	$350

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net income (loss)	($10,500)	$16,589	($34,021)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation and amortization	179	419	774
(Gains) losses on sales of fixed assets	'	-125	214
Intangible impairment charge	0	576	0
Deferred income tax	0	-228	0
Change in contingent consideration liability	0	1,400	0
Expenses for share-based compensation awards	'	2,875	2,903
Acquisition of subsidiary escrow shares returned	'	-82	0
Changes in assets and liabilities:	'	'	'
(Increase) decrease in accounts receivable	'	-38,788	6,240
(Increase) decrease in other current assets	'	-2,259	1,041
Decrease in other assets	'	2,208	0
(Decrease) in accounts payable and accrued expenses	'	-473	-2,565
(Decrease) in deferred revenue - current	'	0	-833
(Decrease) in other liabilities	'	-2	-163
Net cash used in operating activities	'	-17,890	-26,410
Cash flows from investing activities:	'	'	'
Cash acquired in acquisition of subsidiary	'	0	1,888
Capital expenditures	'	-327	-77
Proceeds from sales of fixed assets	'	128	153
Proceeds from redemption of auction rate securities	'	0	1,100
Net cash (used in) provided by investing activities	'	-199	3,064
Cash flows from financing activities:	'	'	'
Equity issuance costs in connection with acquisition of subsidiary	'	0	-45
Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses	'	37,459	40,079
Proceeds from the exercise of stock options	'	0	71
Net cash provided by financing activities	'	37,459	40,105
Net increase in cash and cash equivalents	'	19,370	16,759
Cash and cash equivalents at beginning of period	'	65,860	58,838
Cash and cash equivalents at end of period	75,597	85,230	75,597
Supplemental disclosure of cash flow information:	'	'	'
Contingent consideration liability	15,900	17,100	15,900
Stock acquisition consideration	$11,265	'	$11,265

Interim_Financial_Statements

Interim Financial Statements	9 Months Ended
	Sep. 30, 2014
Interim Financial Statements [Abstract]	'
Interim Financial Statements	'
	1.  Interim Financial Statements
	Progenics Pharmaceuticals, Inc. develops innovative medicines for oncology. Our clinical development efforts center on late-stage oncology assets. We are conducting a phase 2 clinical trial of our therapeutic candidate for prostate cancer, PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC), and have recently completed a phase 2 trial of 1404 (trofolastat), an imaging agent candidate also for prostate cancer. We are resuming a pivotal phase 2 clinical trial of Azedra™, our ultra-orphan radiotherapy candidate for pheochromocytoma.
	We have licensed our first commercial drug, Relistor® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid induced constipation (OIC), to Salix Pharmaceuticals, Inc., which in September 2014 received an expanded approval from the U.S. Food and Drug Administration for the treatment of OIC in patients taking opioids for chronic non-cancer pain. We have partnered other internally-developed or acquired compounds and technologies with third parties. We continue to consider opportunities for strategic collaborations, out-licenses and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs, and may in the future also in-license or acquire additional oncology compounds and/or programs.
	We fund our operations to a significant extent from capital-raising. Early this year, we raised $37.5 million in an underwritten public offering of 8.75 million shares of common stock, and entered into an agreement with an investment bank under which we may sell from time to time up to $50 million of our stock. Our current principal sources of revenue from operations are royalty, milestone and revenue-sharing payments from Salix's development and commercialization of Relistor.
	Progenics commenced principal operations in 1988, became publicly traded in 1997 and throughout has been engaged primarily in research and development efforts, establishing corporate collaborations and related activities. Certain of our intellectual property rights are held by wholly owned subsidiaries. All of our operations are conducted at our facilities in Tarrytown, New York. We operate under a single research and development segment.
	Funding and Financial Matters. At September 30, 2014 we held $85.23 million in cash and cash equivalents, a $0.12 million decrease from the second quarter-end, and a $19.37 million increase from $65.86 million at 2013 year-end. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. We expect to require additional funding in the future, the availability of which is never guaranteed and may be uncertain. We expect that we may continue to incur operating losses for the foreseeable near future.
	Our interim Consolidated Financial Statements included in this report have been prepared in accordance with applicable presentation requirements, and accordingly do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America (GAAP). In the opinion of management, these financial statements reflect all adjustments, consisting primarily of normal recurring accruals necessary for a fair statement of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Our interim financial statements should be read in conjunction with the financial statements and notes thereto contained in our 2013 Annual Report on Form 10-K. The year-end consolidated balance sheet data in these financial statements were derived from audited financial statements, but do not include all disclosures required by GAAP. Certain amounts have been reclassified in prior periods' financial statements to conform to the current presentation. This includes the reclassification of (i) certain expenses for share-based compensation from research and development to general and administrative expenses and (ii) certain non-cash items from general and administrative expenses to intangible impairment charges and change in contingent consideration liability, which reclassifications had no effect on total expenses as previously reported.

Recently_Issued_Accounting_Sta

Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2014
Recently Issued Accounting Standards [Abstract]	'
Recently Issued Accounting Standards [Text Block]	'
	2.  Recently Issued Accounting Standards
	In May 2014, the FASB issued ASU No. 2014-09, which provides a single model for revenue arising from contracts with customers and supersedes current revenue recognition guidance. This ASU provides that an entity should recognize revenue to depict transfers of promised goods or services to customers in amounts reflecting the consideration to which the entity expects to be entitled in the transaction by: (1) identifying the contract; (2) identifying the contract's performance obligations; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations; and (5) recognizing revenue when or as the entity satisfies the performance obligations. The ASU will be effective for annual reporting periods beginning after December 15, 2016, including interim periods. Early adoption is not permitted. The guidance permits companies to apply the requirements either retrospectively to all prior periods presented or in the year of adoption through a cumulative adjustment. We are evaluating the prospective impact of the pending adoption of this ASU on our consolidated financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. This ASU will explicitly require management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective in the first annual period ending after December 15, 2016, unless we adopt it earlier. We are evaluating the prospective impact of the pending adoption of this ASU on our consolidated financial statements.

Revenue_Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2014
Revenue Recognition [Abstract]	'
Revenue Recognition	'
	3.  Revenue Recognition
	The Company recognizes revenue from all sources based on the provisions of the SEC's Staff Accounting Bulletin (SAB) No. 104 (SAB 104) and ASC 605 Revenue Recognition. Under ASC 605, delivered items are separate units of accounting, provided (i) the delivered items have value to a collaborator on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in our control. We recognize revenue for payments that are contingent upon performance solely by our collaborator immediately upon the achievement of the defined event if we have no related performance obligations. A separate update to ASC 605 provides guidance on the criteria that should be met when determining whether the milestone method of revenue recognition is appropriate.
	There have been no changes to our revenue recognition accounting policies in 2014 to date. These policies are disclosed in Note 3 to the consolidated financial statements included in our 2013 Annual Report on Form 10-K.
	During 2014 to date, we have recognized as third quarter revenue a $40.0 million milestone receivable from Salix upon U.S. marketing approval for subcutaneous Relistor in non-cancer pain patients in September (paid pursuant to the Salix license in October) and a $1.0 million milestone payment from FUJIFILM RI Pharma in the first quarter of 2014.
	During the third quarter of 2014, Salix entered into an agreement with Lupin Limited for distribution of Relistor in Canada. We have not recognized any revenue in the quarter, since terms of the Salix and Progenics negotiations were not fixed and determinable as of the end of the quarter.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Net Loss Per Share [Abstract]	'
Net Loss Per Share	'
	4.  Net Income (Loss) Per Share
	Our basic net income (loss) per share amounts have been computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. For the current reporting periods, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect of stock options (determined using the treasury stock method) and  contingent consideration liability (arising from our 2013 acquisition of Molecular Insight). For the corresponding periods of 2013, we reported net losses, and therefore potential dilutive common shares were not included in the computation of diluted net loss per share since it would have been anti-dilutive. The calculations of net income (loss) per share, basic and diluted, are as follows:
		Net Income (Loss)			Weighted Average Common Shares		Per Share
		(Numerator)			(Denominator)		Amount
					(in thousands)
	Three months ended September 30, 2014
	Basic	$	36,975			69,556	$	0.53
	Dilutive effect of contingent consideration liability		500			3,295
	Dilutive effect of stock options		-			28
	Diluted	$	37,475			72,879	$	0.51
	Nine months ended September 30, 2014
	Basic	$	16,589			67,712	$	0.24
	Dilutive effect of contingent consideration liability		-			-
	Dilutive effect of stock options		-			15
	Diluted	$	16,589			67,727	$	0.24
	Three months ended September 30, 2013
	Basic and diluted	$	(10,500	)		60,599	$	(0.17	)
	Nine months ended September 30, 2013
	Basic and diluted	$	(34,021	)		54,104	$	(0.63	)
	For these periods, anti-dilutive common shares excluded from diluted per share amounts consist of the following:
		Three Months Ended September 30,
		2014					2013
		Weighted			Weighted		Weighted			Weighted
		Average			Average		Average			Average
		Number			Exercise Price		Number			Exercise Price
		(in thousands)					(in thousands)
	Options		5,267		$	10.23		6,068		$	11.14
		Nine Months Ended September 30,
		2014					2013
		Weighted			Weighted		Weighted			Weighted
		Average			Average		Average			Average
		Number			Exercise Price		Number			Exercise Price
		(in thousands)					(in thousands)
	Options		5,357		$	10.31		6,047		$	11.69
	Contingent consideration liability		3,295					-
	Total		8,652					6,047

InProcess_Research_and_Develop

In-Process Research and Development and Goodwill	9 Months Ended
	Sep. 30, 2014
In-Process Research and Development and Goodwill [Abstract]	'
In-Process Research and Development and Goodwill [Text Block]	'
	5.  In-Process Research and Development and Goodwill
	The fair values of in-process research and development (IPR&D) acquired in business combinations are capitalized. The Company utilizes the "income method" which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using a discount rate we consider appropriate. This analysis is performed for each IPR&D project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&D intangible assets which are determined to have a decline in their fair value are adjusted downward and an impairment loss is recognized in the Consolidated Statements of Operations. These are tested at least annually or when a triggering event occurs that could indicate a potential impairment.
	Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company determines whether goodwill may be impaired by comparing the fair value of the reporting unit (the Company has determined that it has only one reporting unit for this purpose, which includes Molecular Insight), calculated as the product of shares outstanding and the share price as of the end of a period, to its carrying value (for this purpose, the Company's Total stockholders' equity). No goodwill impairment has been recognized as of September 30, 2014 or 2013.
	A third quarter review of our Onalta intangible asset resulted in a $560 impairment of the indefinite-lived balance and a $16 impairment of the finite-lived balance, with the corresponding impairment charges recorded in the Consolidated Statements of Operations.
	The following table summarizes the activity related to the finite-lived intangible asset for the nine months ended September 30, 2014:
		Finite-lived
		intangible assets
	Balance at January 1, 2014	$	19
	Amortization expense		(3	)
	Impairment		(16	)
	Balance at September 30, 2014	$	-
	The following table reflects, prior to the third quarter write-off, the components of the finite-lived intangible asset as of December 31, 2013:
	As of December 31, 2013	Gross			Accumulated			Net Carrying
		Amount			Amortization			Value
	Finite lived intangible assets	$	21		$	2		$	19
	Total	$	21		$	2		$	19
	The weighted-average remaining life of the finite-lived intangible assets was approximately five years at December 31, 2013.
	Amortization expense was calculated on a straight-line basis over the estimated useful life of the asset. Amortization expense for the three and nine months ended September 30, 2014 was $1 and $3, respectively.
	The following tables summarize the activity related to the Company's goodwill and indefinite lived IPR&D:
		Goodwill			IPR&D
	Balance at January 1, 2014	$	7,702		$	31,360
	Impairment		-			(560	)
	Balance at September 30, 2014	$	7,702		$	30,800
		Goodwill			IPR&D
	Balance at January 1, 2013	$	-		$	-
	Increase related to acquisition		7,702			32,300
	Balance at September 30, 2013	$	7,702		$	32,300

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	6.  Fair Value Measurements
	We record auction rate securities at fair value in the accompanying Consolidated Balance Sheets in accordance with ASC 320 Investments – Debt and Equity Securities. The change in the fair value of these investments is recorded as a component of other comprehensive income (loss) (see Note 3. Summary of Significant Accounting Policies - Fair Value Measurements in the notes to consolidated financial statements included in our 2013 Annual Report on Form 10-K). We also record the contingent consideration liability resulting from the MIP acquisition at fair value in accordance with ASC 820-10-50.
	The following tables present our money market funds and auction rate securities and contingent consideration liability measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy:
					Fair Value Measurements at September 30, 2014
		Balance at			Quoted Prices in Active Markets for Identical Assets			Significant Other Observable Inputs				Significant Unobservable Inputs
		30-Sep-14			(Level 1)			(Level 2)				(Level 3)
	Assets:
	Money market funds	$	70,397		$	70,397		$	-			$	-
	Auction rate securities		2,208			-			-				2,208
	Total Assets	$	72,605		$	70,397		$	-			$	2,208
	Liability:
	Contingent consideration	$	17,100		$	-		$	-			$	17,100
	Total Liability	$	17,100		$	-		$	-			$	17,100
					Fair Value Measurements at December 31, 2013
		Balance at			Quoted Prices in Active Markets for Identical Assets			Significant Other Observable Inputs				Significant Unobservable Inputs
		31-Dec-13			(Level 1)			(Level 2)				(Level 3)
	Assets:
	Money market funds	$	60,364		$	60,364		$	-			$	-
	Auction rate securities		2,208			-			-				2,208
	Total Assets	$	62,572		$	60,364		$	-			$	2,208
	Liability:
	Contingent consideration	$	15,700		$	-		$	-			$	15,700
	Total Liability	$	15,700		$	-		$	-			$	15,700
	At September 30, 2014 we held $2,208 in auction rate securities which are classified as Level 3 and in current assets as noted below. The fair value of these securities includes U.S. government subsidized securities collateralized by student loan obligations, with maturities greater than 10 years. Under the securities' terms we would not realize cash in respect of the principal amount of these securities until the issuer calls or restructures the security, the security reaches any scheduled maturity and is paid, or a buyer outside the auction process emerges. We have to date received all scheduled interest payments on these securities, which, in the event of auction failure, are reset according to contractual terms in the governing instruments.
	The valuation of auction rate securities we held at September 30, 2014 is based on Level 3 unobservable inputs which consist of our internal analysis of (i) timing of expected future successful auctions or issuer calls of the securities, (ii) collateralization of underlying assets of the security and (iii) credit quality of the security. Significant increases or decreases in the redemption period or discount rates would result in a significantly lower or higher, respectively, fair value measurement. The temporary impairment amount associated with these securities, the duration of which is greater than 12 months, remained unchanged from year-end 2013 at $192, which is reflected as part of accumulated other comprehensive loss on our accompanying Consolidated Balance Sheets. Based on our re-evaluation for this quarter, we continue to believe that we have the ability to hold these securities until recovery of fair value. Due to the uncertainty related to the liquidity in the auction rate security market and therefore when individual positions may be liquidated, we classified these auction rate securities as long-term assets on our accompanying Consolidated Balance Sheet as of December 31, 2013. We continue to monitor markets for our investments and consider the impact, if any, of market conditions on the fair market value of our investments. We do not believe the carrying values of our investments are other than temporarily impaired and therefore expect the positions will eventually be liquidated without significant loss. Due to redemption of the auction rate securities after third quarter-end, these securities have been classified as current assets as of September 30, 2014 (see Note 11. Subsequent Event).
	The estimated fair value of the contingent consideration liability of $17.1 million as of September 30, 2014, represents future potential milestone payments to former MIP stockholders. The Company considers this liability a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flow and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs were the probabilities of achieving regulatory approval of the development projects and subsequent commercial success, and discount rates.
	Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement, respectively. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in the Consolidated Statements of Operations.
	The following table presents quantitative information pertaining to the September 30, 2014 fair value measurement of the Level 3 inputs. The assumptions remained unchanged since December 31, 2013:
		Fair Value as of September 30, 2014		Fair Value as of December 31, 2013			Valuation Technique	Unobservable Input		Range
										(Weighted Average)
	Asset:
	Auction rate securities	$	2,208	$	2,208		Discounted cash flow model	Redemption period		5 to 15 years
										(6 years)
								Discount rate			0.25% - 3.00%
											-1.55%
	Contingent consideration liability:
	Azedra commercialization	$	2,400	$	2,300		Probability adjusted discounted cash flow model	Probability of success			40%
								Period of milestone expected achievement			2017
								Discount rate			10%
	1404 commercialization	$	2,200	$	2,000		Probability adjusted discounted cash flow model	Probability of success			31%
								Period of milestone expected achievement			2018
								Discount rate			10%
	MIP-1095 commercialization	$	500	$	500		Probability adjusted discounted cash flow model	Probability of success			19%
								Period of milestone expected achievement			2021
								Discount rate			10%
	Net sales targets	$	12,000	$	10,900		Monte-Carlo simulation	Probability of success			19% - 40%
											-32.80%
								Period of milestone expected achievement			2018 - 2022
								Discount rate			12.50%
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
		Asset – Auction Rate Securities
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
		For the Three Months Ended September 30,
		2014			2013
	Description
	Balance at beginning of period	$	2,208		$	2,208
	Transfers into Level 3		-			-
	Total realized/unrealized gains (losses)
	Included in net income (loss)		-			-
	Included in other comprehensive income (loss)		-			-
	Settlements		-			-
Balance at end of period	$	2,208		$	2,208
Total amount of unrealized gains (losses) for the period included in other comprehensive income (loss) attributable to the change in fair market value of related assets still held at the reporting date	$	-		$	-
	Asset – Auction Rate Securities
	Fair Value Measurements Using Significant
	Unobservable Inputs
	(Level 3)
	For the Nine Months Ended September 30,
	2014			2013
Description
Balance at beginning of period	$	2,208		$	3,240
Transfers into Level 3		-			-
Total realized/unrealized gains (losses)
Included in net income (loss)		-			-
Included in other comprehensive income (loss)		-			68
Settlements		-			(1,100	)
Balance at end of period	$	2,208		$	2,208
Total amount of unrealized gains (losses) for the period included in other comprehensive income (loss) attributable to the change in fair market value of related assets still held at the reporting date	$	-		$	-
	Liability – Contingent Consideration
	Fair Value Measurements Using Significant
	Unobservable Inputs
	(Level 3)
	For the Three Months Ended September 30,
	2014			2013
Description
Balance at beginning of period	$	16,600		$	15,900
Fair value change to contingent consideration included in net income (loss)		500			-
Balance at end of period	$	17,100		$	15,900
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	500		$	-
	Liability – Contingent Consideration
	Fair Value Measurements Using Significant
	Unobservable Inputs
	(Level 3)
	For the Nine Months Ended September 30,
	2014			2013
Description
Balance at beginning of period	$	15,700		$	-
Fair value of contingent consideration – acquisition of Molecular Insight		-			15,900
Fair value change to contingent consideration included in net income (loss)		1,400			-
Balance at end of period	$	17,100		$	15,900
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	1,400		$	-

Accounts_Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2014
Accounts Receivable [Abstract]	'
Accounts Receivable	'
	7.  Accounts Receivable
	Accounts receivable represent amounts due to Progenics from collaborators, royalty obligations owing to us, and sales of research reagents, and at the below dates amounted to:
		30-Sep-14			31-Dec-13
	Collaborators	$	40,023		$	12
	Royalties		1,651			2,862
	Other		3			12
			41,677			2,886
	Less, allowance for doubtful accounts		(10	)		(7	)
	Total	$	41,667		$	2,879

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Accounts Payable and Accrued Expenses	'
	8.  Accounts Payable and Accrued Expenses
	The carrying value of our accounts payable and accrued expenses approximates fair value, as it represents amounts due to vendors and employees which will be satisfied within one year. Accounts payable and accrued expenses at the below dates amounted to:
		30-Sep-14		31-Dec-13
	Accrued consulting and clinical trial costs	$	1,955	$	2,672
	Accrued payroll and related costs		1,807		2,123
	Legal and professional fees		1,340		608
	Accounts payable		566		793
	Other		371		316
	Total	$	6,039	$	6,512

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2014
Restructuring [Abstract]	'
Restructuring	'
	9.  Restructuring
	We incurred a $0.4 million headcount reduction restructuring obligation in the first quarter of 2014, which was fully paid as of the end of the third quarter. A first quarter 2013 headcount reduction resulted in a $1.5 million restructuring obligation paid that year. During the second quarter of 2013, we incurred other exit and contract termination costs, including in connection with termination of a Molecular facilities lease ($0.9 million) and amendment and consolidation of the Company's facilities lease ($0.5 million).
	Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets and research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.
		Severance and Related Benefits			Other Exit			Contract Termination Costs			Total Restructuring Accrual
					Costs
	Balance at December 31, 2013	$	-		$	-		$	-		$	-
	Additions, net		358			-			-			358
	Payments		(146	)		-			-			(146	)
	Balance at March 31, 2014		212			-			-			212
	Additions, net		1			-			-			1
	Payments		(164	)		-			-			(164	)
	Balance at June 30, 2014		49			-			-			49
	Additions, net		-			-			-			-
	Payments		(49	)		-			-			(49	)
	Balance at September 30, 2014	$	-		$	-		$	-		$	-
		Severance and Related Benefits			Other Exit			Contract Termination Costs			Total Restructuring Accrual
					Costs
	Balance at December 31, 2012	$	813		$	-		$	-		$	813
	Additions, net		1,477			-			-			1,477
	Payments		(854	)		-			-			(854	)
	Balance at March 31, 2013		1,436			-			-			1,436
	Additions, net		15			15			1,359			1,389
	Payments		(914	)		(15	)		(1,359	)		(2,288	)
	Balance at June 30, 2013		537			-			-			537
	Additions, net		-			-			-			-
	Payments		(448	)		-			-			(448	)
	Balance at September 30, 2013	$	89		$	-		$	-		$	89

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	10.  Commitments and Contingencies
	In the ordinary course of our business, we enter into agreements with third parties, such as business partners, clinical sites and suppliers, that include usual and customary indemnification provisions. We generally reciprocally agree to indemnify, hold harmless and reimburse indemnified parties for losses suffered or incurred with respect to products or product candidates, use of such products or other actions taken or omitted by the parties. The maximum potential amount of future payments we could be required to make under these indemnification provisions is frequently not limited. We have not incurred material costs to defend lawsuits or settle claims related to these provisions. As a result, the estimated fair value of liabilities relating to indemnification provisions is minimal. We have no liabilities recorded for these provisions as of September 30, 2014 and December 31, 2013.
	Progenics is a party to a proceeding brought by a former employee complaining that the Company violated the anti-retaliation provisions of the federal Sarbanes-Oxley law by terminating the former employee. The Company believes the former employee's claims are without merit and is contesting the matter vigorously. The federal District Court hearing the case issued in July 2013 an order denying our motion for summary judgment dismissing the former employee's complaint, making it likely that the proceeding will continue to trial. Given the continued uncertainty attendant to the proceeding, we continue to accrue related legal expenses, and have accrued other amounts in connection with this proceeding which are not material to these Consolidated Financial Statements.
	In the third quarter of 2014, Progenics and its former licensee of Relistor in Japan, settled all claims between them relating to an arbitration commenced by Progenics in 2013, the parties' October 2008 License Agreement, and the former licensee's development and commercialization of the drug. In connection therewith, the parties exchanged mutual releases and the former licensee paid Progenics $$7.25 million, which has been recorded as other operating income.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	11.  Subsequent Event
	During the fourth quarter of 2014, all of the $2,208 auction rate securities remaining at September 30, 2014 have been redeemed at par, and accordingly classified as current assets as of September 30, 2014.

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Net Loss Per Share [Abstract]	'
Calculation of net loss per share, basic and diluted	'
		Net Income (Loss)			Weighted Average Common Shares		Per Share
		(Numerator)			(Denominator)		Amount
					(in thousands)
	Three months ended September 30, 2014
	Basic	$	36,975			69,556	$	0.53
	Dilutive effect of contingent consideration liability		500			3,295
	Dilutive effect of stock options		-			28
	Diluted	$	37,475			72,879	$	0.51
	Nine months ended September 30, 2014
	Basic	$	16,589			67,712	$	0.24
	Dilutive effect of contingent consideration liability		-			-
	Dilutive effect of stock options		-			15
	Diluted	$	16,589			67,727	$	0.24
	Three months ended September 30, 2013
	Basic and diluted	$	(10,500	)		60,599	$	(0.17	)
	Nine months ended September 30, 2013
	Basic and diluted	$	(34,021	)		54,104	$	(0.63	)
Schedule of antidilutive common shares excluded from computation of diluted earnings per share	'
	For these periods, anti-dilutive common shares excluded from diluted per share amounts consist of the following:
		Three Months Ended September 30,
		2014					2013
		Weighted			Weighted		Weighted			Weighted
		Average			Average		Average			Average
		Number			Exercise Price		Number			Exercise Price
		(in thousands)					(in thousands)
	Options		5,267		$	10.23		6,068		$	11.14
		Nine Months Ended September 30,
		2014					2013
		Weighted			Weighted		Weighted			Weighted
		Average			Average		Average			Average
		Number			Exercise Price		Number			Exercise Price
		(in thousands)					(in thousands)
	Options		5,357		$	10.31		6,047		$	11.69
	Contingent consideration liability		3,295					-
	Total		8,652					6,047

InProcess_Research_and_Develop1

In-Process Research and Development and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2014
In-Process Research and Development and Goodwill [Abstract]	'
Components of finite-lived intangible assets [Text Block]	'
	The following table summarizes the activity related to the finite-lived intangible asset for the nine months ended September 30, 2014:
		Finite-lived
		intangible assets
	Balance at January 1, 2014	$	19
	Amortization expense		(3	)
	Impairment		(16	)
	Balance at September 30, 2014	$	-
	The following table reflects, prior to the third quarter write-off, the components of the finite-lived intangible asset as of December 31, 2013:
	As of December 31, 2013	Gross			Accumulated			Net Carrying
		Amount			Amortization			Value
	Finite lived intangible assets	$	21		$	2		$	19
	Total	$	21		$	2		$	19
Activity related to goodwill and indefinite lived intangible assets [Text Block]	'
	The following tables summarize the activity related to the Company's goodwill and indefinite lived IPR&D:
		Goodwill			IPR&D
	Balance at January 1, 2014	$	7,702		$	31,360
	Impairment		-			(560	)
	Balance at September 30, 2014	$	7,702		$	30,800
		Goodwill			IPR&D
	Balance at January 1, 2013	$	-		$	-
	Increase related to acquisition		7,702			32,300
	Balance at September 30, 2013	$	7,702		$	32,300

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
Assets and liabilities measured at fair value on recurring basis	'
	The following tables present our money market funds and auction rate securities and contingent consideration liability measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy:
					Fair Value Measurements at September 30, 2014
		Balance at			Quoted Prices in Active Markets for Identical Assets			Significant Other Observable Inputs				Significant Unobservable Inputs
		30-Sep-14			(Level 1)			(Level 2)				(Level 3)
	Assets:
	Money market funds	$	70,397		$	70,397		$	-			$	-
	Auction rate securities		2,208			-			-				2,208
	Total Assets	$	72,605		$	70,397		$	-			$	2,208
	Liability:
	Contingent consideration	$	17,100		$	-		$	-			$	17,100
	Total Liability	$	17,100		$	-		$	-			$	17,100
					Fair Value Measurements at December 31, 2013
		Balance at			Quoted Prices in Active Markets for Identical Assets			Significant Other Observable Inputs				Significant Unobservable Inputs
		31-Dec-13			(Level 1)			(Level 2)				(Level 3)
	Assets:
	Money market funds	$	60,364		$	60,364		$	-			$	-
	Auction rate securities		2,208			-			-				2,208
	Total Assets	$	62,572		$	60,364		$	-			$	2,208
	Liability:
	Contingent consideration	$	15,700		$	-		$	-			$	15,700
	Total Liability	$	15,700		$	-		$	-			$	15,700
Quantitative information for fair value measurement of Level 3	'
	The following table presents quantitative information pertaining to the September 30, 2014 fair value measurement of the Level 3 inputs. The assumptions remained unchanged since December 31, 2013:
		Fair Value as of September 30, 2014		Fair Value as of December 31, 2013			Valuation Technique	Unobservable Input		Range
										(Weighted Average)
	Asset:
	Auction rate securities	$	2,208	$	2,208		Discounted cash flow model	Redemption period		5 to 15 years
										(6 years)
								Discount rate			0.25% - 3.00%
											-1.55%
	Contingent consideration liability:
	Azedra commercialization	$	2,400	$	2,300		Probability adjusted discounted cash flow model	Probability of success			40%
								Period of milestone expected achievement			2017
								Discount rate			10%
	1404 commercialization	$	2,200	$	2,000		Probability adjusted discounted cash flow model	Probability of success			31%
								Period of milestone expected achievement			2018
								Discount rate			10%
	MIP-1095 commercialization	$	500	$	500		Probability adjusted discounted cash flow model	Probability of success			19%
								Period of milestone expected achievement			2021
								Discount rate			10%
	Net sales targets	$	12,000	$	10,900		Monte-Carlo simulation	Probability of success			19% - 40%
											-32.80%
								Period of milestone expected achievement			2018 - 2022
								Discount rate			12.50%
Summary of activities in financial instruments with Level 3 inputs	'
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
		Asset – Auction Rate Securities
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
		For the Three Months Ended September 30,
		2014			2013
	Description
	Balance at beginning of period	$	2,208		$	2,208
	Transfers into Level 3		-			-
	Total realized/unrealized gains (losses)
	Included in net income (loss)		-			-
	Included in other comprehensive income (loss)		-			-
	Settlements		-			-
	Balance at end of period	$	2,208		$	2,208
	Total amount of unrealized gains (losses) for the period included in other comprehensive income (loss) attributable to the change in fair market value of related assets still held at the reporting date	$	-		$	-
		Asset – Auction Rate Securities
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
		For the Nine Months Ended September 30,
		2014			2013
	Description
	Balance at beginning of period	$	2,208		$	3,240
	Transfers into Level 3		-			-
	Total realized/unrealized gains (losses)
	Included in net income (loss)		-			-
	Included in other comprehensive income (loss)		-			68
	Settlements		-			(1,100	)
	Balance at end of period	$	2,208		$	2,208
	Total amount of unrealized gains (losses) for the period included in other comprehensive income (loss) attributable to the change in fair market value of related assets still held at the reporting date	$	-		$	-
		Liability – Contingent Consideration
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
		For the Three Months Ended September 30,
		2014			2013
	Description
	Balance at beginning of period	$	16,600		$	15,900
	Fair value change to contingent consideration included in net income (loss)		500			-
	Balance at end of period	$	17,100		$	15,900
	Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	500		$	-
		Liability – Contingent Consideration
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
		For the Nine Months Ended September 30,
		2014			2013
	Description
	Balance at beginning of period	$	15,700		$	-
	Fair value of contingent consideration – acquisition of Molecular Insight		-			15,900
	Fair value change to contingent consideration included in net income (loss)		1,400			-
	Balance at end of period	$	17,100		$	15,900
	Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	1,400		$	-

Accounts_Receivable_Tables

Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2014
Accounts Receivable [Abstract]	'
Accounts Receivable	'
	7.  Accounts Receivable
	Accounts receivable represent amounts due to Progenics from collaborators, royalty obligations owing to us, and sales of research reagents, and at the below dates amounted to:
		30-Sep-14			31-Dec-13
	Collaborators	$	40,023		$	12
	Royalties		1,651			2,862
	Other		3			12
			41,677			2,886
	Less, allowance for doubtful accounts		(10	)		(7	)
	Total	$	41,667		$	2,879

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of accounts payable and accrued expenses	'
		30-Sep-14		31-Dec-13
	Accrued consulting and clinical trial costs	$	1,955	$	2,672
	Accrued payroll and related costs		1,807		2,123
	Legal and professional fees		1,340		608
	Accounts payable		566		793
	Other		371		316
	Total	$	6,039	$	6,512

Restructuring_Tables

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring [Abstract]	'
Activity in restructuring accrual	'
	Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets and research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.
		Severance and Related Benefits			Other Exit			Contract Termination Costs			Total Restructuring Accrual
					Costs
	Balance at December 31, 2013	$	-		$	-		$	-		$	-
	Additions, net		358			-			-			358
	Payments		(146	)		-			-			(146	)
	Balance at March 31, 2014		212			-			-			212
	Additions, net		1			-			-			1
	Payments		(164	)		-			-			(164	)
	Balance at June 30, 2014		49			-			-			49
	Additions, net		-			-			-			-
	Payments		(49	)		-			-			(49	)
	Balance at September 30, 2014	$	-		$	-		$	-		$	-
		Severance and Related Benefits			Other Exit			Contract Termination Costs			Total Restructuring Accrual
					Costs
	Balance at December 31, 2012	$	813		$	-		$	-		$	813
	Additions, net		1,477			-			-			1,477
	Payments		(854	)		-			-			(854	)
	Balance at March 31, 2013		1,436			-			-			1,436
	Additions, net		15			15			1,359			1,389
	Payments		(914	)		(15	)		(1,359	)		(2,288	)
	Balance at June 30, 2013		537			-			-			537
	Additions, net		-			-			-			-
	Payments		(448	)		-			-			(448	)
	Balance at September 30, 2013	$	89		$	-		$	-		$	89

Interim_Financial_Statements_D

Interim Financial Statements (Details) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Public Offering [Abstract]	'	'	'	'	'
Proceeds	'	$37,459	$40,079	'	'
Public Offering shares issued	'	8,750,000	'	'	'
Proceeds from future sales of common stock under an agreement with investment bank	50,000	50,000	'	'	'
Funding and Financial Matters [Abstract]	'	'	'	'	'
Cash and cash equivalents at end of period	85,230	85,230	75,597	65,860	58,838
Increase (decrease) in cash and cash equivalents	($117)	$19,370	$16,759	'	'
Minimum number of years cash will fund operations (in years)	'	'1 year	'	'	'

Revenue_Recognition_Details

Revenue Recognition (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Revenue Recognition [Abstract]	'	'
Milestone Revenue from Fuji	'	$1
Milestone Revenue from Salix	$40	'

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net Income (Loss) (Numerator) [Abstract]	'	'	'	'
Net Income (Loss) Available to Common Stockholders, Basic	$36,975	'	$16,589	'
Dilutive effect of potential settlement of contingent consideration liability	500	'	0	'
Net Income (Loss) Available to Common Stockholders, Diluted	37,475	'	16,589	'
Net loss basic and diluted	$36,975	($10,500)	$16,589	($34,021)
Weighted Average Common Shares (Denominator) Abstract	'	'	'	'
Weighted Average Number of Shares Outstanding, Basic	69,556	60,599	67,712	54,104
Weighted Average Number of Shares Outstanding, Diluted	72,879	60,599	67,727	54,104
Dilutive effect of potential settlement of contingent consideration liability (shares)	3,295	'	0	'
Weighted Average Number Diluted Shares Outstanding Adjustment	28	'	15	'
Shares outstanding, basic and diluted (in shares)	'	60,599	'	54,104
Per share amount [Abstract]	'	'	'	'
Earnings Per Share, Basic	$0.53	($0.17)	$0.24	($0.63)
Earnings Per Share, Diluted	$0.51	($0.17)	$0.24	($0.63)
Net loss per share, basic and diluted (in dollars per share)	'	($0.17)	'	($0.63)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted Average Number (in shares)	'	'	8,652	6,047
Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted Average Number (in shares)	5,267	6,068	5,357	6,047
Weighted Average Exercise Price (in dollars per share)	$10.23	$11.14	$10.31	$11.69
Contingent Consideration Liability [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted Average Number (in shares)	'	'	3,295	0

InProcess_Research_and_Develop2

In-Process Research and Development and Goodwill (Details) (USD $)	3 Months Ended	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Finite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Finite-Lived Intangible Assets, Net	'	$19	'	'	'
Amortization of Intangible Assets	-1	-3	'	'	'
Impairment of Intangible Assets, Finite-lived	-16	-16	'	'	'
Finite-Lived Intangible Assets, Net	0	0	'	19	'
Onalta Finite Lived IPR&D Impairment	16	16	'	'	'
Finite-Lived Intangible Assets, Gross	'	'	'	21	'
Finite-Lived Intangible Assets, Accumulated Amortization	'	'	'	2	'
Finite-Lived Intangible Assets, Net, Total	0	0	'	19	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'5 years	'
Amortization of Intangible Assets	1	3	'	'	'
Goodwill and indefinite lived in-process research and development [Abstract]	'	'	'	'	'
Onalta Indefinite Lived IPR&D Impairment	560	'	'	'	'
Goodwill	7,702	7,702	7,702	7,702	0
Goodwill, Acquired During Period	'	0	7,702	'	'
Intangible Assets Acquired During Period	'	0	32,300	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	30,800	30,800	32,300	31,360	0
Impairment of Indefinite Intangible Assets (Excluding Goodwill)	'	($560)	$0	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Azedra commercialization [Member]

Azedra commercialization [Member]

MIP - 1404 commercialization [Member]

MIP - 1404 commercialization [Member]

MIP-1095 commercialization [Member]

MIP-1095 commercialization [Member]

MIP-1095 commercialization [Member]

Net sales targets [Member]

Net sales targets [Member]

Net sales targets [Member]

Net sales targets [Member]

Net sales targets [Member]

Net sales targets [Member]

Net sales targets [Member]

Net sales targets [Member]

Contingent Consideration Liability [Member]

Contingent Consideration Liability [Member]

Contingent Consideration Liability [Member]

Contingent Consideration Liability [Member]

U.S. Government Subsidized Securities [Member]

Recurring [Member]

Recurring [Member]

Recurring [Member]

Recurring [Member]

Recurring [Member]

Recurring [Member]

Recurring [Member]

Recurring [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Weighted average [Member]

Weighted average [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Weighted average [Member]

Weighted average [Member]

Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration liability

$17,100

$15,700

$15,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$17,100

$15,700

$0

$0

$0

$0

$17,100

$15,700

Money Market Funds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70,397

60,364

70,397

60,364

0

0

0

0

Auction Rate Securities

2,208

2,208

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,208

2,208

2,208

0

0

0

0

2,208

2,208

Asset, total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

72,605

62,572

70,397

60,364

0

0

2,208

2,208

Liability, total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,100

15,700

0

0

0

0

17,100

15,700

Maturity period of US government subsidized securities (in years)

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Duration of securities subject to temporary impairment, minimum (in months)

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of temporary impairment

192

192

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at beginning of period

'

'

'

2,208

2,208

2,208

3,240

3,240

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,600

15,900

15,700

0

'

'

'

'

'

'

'

'

'

Transfers into Level 3

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total realized/unrealized gains (losses)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Included in net income (loss)

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Included in other comprehensive incomet (loss)

'

'

'

0

0

0

68

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Settlements

'

'

'

0

0

0

-1,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of contingent consideration - acquisition of Molecular Insight

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

15,900

'

'

'

'

'

'

'

'

'

Fair value change to contingent consideration included in net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500

0

1,400

0

'

'

'

'

'

'

'

'

'

Balance at end of period

'

'

'

2,208

2,208

2,208

2,208

2,208

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,100

15,900

17,100

15,900

'

'

'

'

'

'

'

'

'

Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500

0

1,400

0

'

'

'

'

'

'

'

'

'

Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Measurements, Quantitative Information

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of milestone expected achievement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2017

'2017

'2018

'2018

'

'2021

'2021

'

'

'2018

'2018

'2022

'2022

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value

'

'

'

$2,208

'

$2,208

'

$2,208

'

'

'

'

'

'

$2,400

$2,300

$2,200

$2,000

'

$500

$500

$12,000

$10,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Valuation technique

'

'

'

'

'

'Discounted cash flow model

'

'Discounted cash flow model

'

'

'

'

'

'

'Probability adjusted discounted cash flow model

'Probability adjusted discounted cash flow model

'Probability adjusted discounted cash flow model

'Probability adjusted discounted cash flow model

'

'Probability adjusted discounted cash flow model

'Probability adjusted discounted cash flow model

'Monte-Carlo simulation

'Monte-Carlo simulation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption period

'

'

'

'

'

'

'

'

'5 years

'5 years

'15 years

'15 years

'6 years

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount Rate

'

'

'

'

'

'

'

'

0.25%

0.25%

3.00%

3.00%

1.55%

1.55%

10.00%

10.00%

10.00%

10.00%

10.00%

'

10.00%

12.50%

12.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Probability of success

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

40.00%

31.00%

31.00%

'

19.00%

19.00%

'

'

19.00%

19.00%

40.00%

40.00%

32.80%

32.80%

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	$41,667	$2,879
Allowance for Doubtful Accounts Receivable	-10	-7
Collaborators [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	40,023	12
Royalties [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	1,651	2,862
Other Receivables [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	3	12
Subtotal [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	$41,677	$2,886

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Payable and Accrued Expenses [Abstract]	'	'
Accrued consulting and clinical trial costs	$1,955	$2,672
Accrued payroll and related costs	1,807	2,123
Restructuring accrual	0	0
Legal and professional fees	1,340	608
Accounts payable	566	793
Other	371	316
Total	$6,039	$6,512

Restructuring_Details

Restructuring (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Restructuring [Abstract]	'	'	'	'	'	'
Restructuring accrual of severance and related benefits	'	'	$400	'	'	$1,500
Lease termination payments - Molecular	'	'	'	'	900	'
Lease termination payments - Progenics	'	'	'	'	500	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'
Balance at beginning of period	49	212	0	537	1,436	813
Additions, net	0	1	358	0	1,389	1,477
Payments	-49	-164	-146	-448	-2,288	-854
Balance at end of period	0	49	212	89	537	1,436
Severance and Related Benefits [Member]	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'
Balance at beginning of period	49	212	0	537	1,436	813
Additions, net	0	1	358	0	15	1,477
Payments	-49	-164	-146	-448	-914	-854
Balance at end of period	0	49	212	89	537	1,436
Other Exit Costs [Member]	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'
Balance at beginning of period	0	0	0	0	0	0
Additions, net	0	0	0	0	15	0
Payments	0	0	0	0	-15	0
Balance at end of period	0	0	0	0	0	0
Contract Termination Costs [Member]	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'
Balance at beginning of period	0	0	0	0	0	0
Additions, net	0	0	0	0	1,359	0
Payments	0	0	0	0	-1,359	0
Balance at end of period	$0	$0	$0	$0	$0	$0

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Commitments and Contingencies [Abstract]	'
Arbitration Settlement Payment From Ono	$7.25

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Subsequent Events [Abstract]	'	'
Auction rate securities - current	$2,208	$0